Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CCNH | P51946 | 1/20 | 0.45 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 3/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187491 | 0.87 | XDH (0.57) | SYKKDRSIRT2SIRT1SIRT3 | |
| SCHEMBL4164153 | 0.86 | PARP1 (0.49) | PARP1SYKKDRSIRT2SIRT1 | |
| SCHEMBL4191929 | 0.85 | XDH (0.61) | PARP1SYKKDRSIRT2SIRT1 | |
| SCHEMBL4187667 | 0.82 | L3MBTL1 (0.46) | KDRXDHSLC22A12NPC1FYN | |
| SCHEMBL4182331 | 0.82 | SIRT2 (0.71) | SYKKDRSIRT2SIRT1SIRT3 | |
| SCHEMBL4199231 | 0.81 | XDH (0.57) | PARP1SYKKDRSIRT2SIRT1 | |
| SCHEMBL4194432 | 0.81 | TSHR (0.54) | SYKMEN1NPC1KMT2AABL1 | |
| SCHEMBL4191642 | 0.79 | XDH (0.61) | SYKKDRSIRT2SIRT1SIRT3 | |
| SCHEMBL4199153 | 0.79 | ABL1 (0.48) | PARP1SYKKDRSIRT2SIRT1 | |
| SCHEMBL4147232 | 0.79 | XDH (0.59) | PARP1KDRSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | PARP1 1375/4885SYK 441/4885KDR 655/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | PARP1 1519/4885SYK 1941/4885KDR 4228/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | PARP1 1519/4885SYK 1941/4885KDR 4228/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | PARP1 1519/4885SYK 1941/4885KDR 4228/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | PARP1 428/4885SYK 3754/4885KDR 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.